Sanofi's Dupixent can reduce severe asthma attacks in children

sanofi's biotherapy Dupilumab has been a success in the latest data from a major Phase III clinical trial.the study assessed the role of Dupixent in children between the ages of 6 and 11 with moderate to severe asthma, with Sanofi's drugs reaching primary and secondary ends.In a broad group of patients with type 2 inflammatory asthma - elevated eosomal cells (EOS) or exhaled nitric oxide (FeNO) - Dupixent can significantly reduce asthma attacks and improve lung function when added to the standard of care.In the Dupixent group, participants had a 65 percent and 59
percent lower rate of severe asthma attacks over the
.more than 90 percent of children in the trial also suffered from at least one type of type 2 inflammation, including epithelitis and eosinophilic esophedritis.safety results are usually consistent with known safety in patients 12 years of age and older with moderate to severe asthma.more than a year, Dupixent's overall adverse event rate was 83
percent
, and the placebo was 80,
percent
. The most common adverse events associated with Dupixent and placebo include injection site reactions, viral upper respiratory tract infections, and increased eosinophils.John Reed, head of global research and development at Sanofi, said: "Children with uncontrollable moderate to severe asthma often have difficulty breathing, mainly because of impaired lung function, which can have a serious impact on their quality of life. "" Dupixent is the only biologic agent that improves lung function in children in phase III clinical trials, usually consistent with the results in adolescent and adult trials. These positive data are
especially
encouraging for young children who are struggling to control their uncontrolled asthma. ”（cyy123.com）